VF Corp, Verve Therapeutics And Some Other Big Stocks Moving Lower On Monday

U.S. stocks traded lower, with the Dow Jones dropping over 200 points on Monday. Here are some big stocks recording losses in today’s session.

• Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA) shares tumbled 25% to $9.96. Meihua International Medical Technologies named Mr. Xin Wang as new CEO and Mr. Lianzhang Zhao as CFO.
• Amprius Technologies, Inc. (NYSE: AMPX) fell 21.8% to $8.06. Amprius Technologies, last month, posted a Q3 loss of $0.06 per share.
• Verve Therapeutics, Inc. (NASDAQ: VERV) declined 15.9% to $20.18 after the company announced it received a clinical hold letter from the FDA that outlined information required to resolve the clinical hold on Verve-101.
• Atour Lifestyle Holdings Limited (NASDAQ: ATAT) dropped 10.6% to $15.80.
• Nayax Ltd. (NASDAQ: NYAX) shares declined 10.4% to $18.85. Jefferies, on Friday, initiated coverage on Nayax with a Hold rating and announced a price target of $22.
• Latham Group, Inc. (NASDAQ: SWIM) fell 10.3% to $3.2010.
• Rackspace Technology, Inc. (NASDAQ: RXT) fell 10.2% to $4.3550 following a "security incident" which caused an outage in its Hosted Exchange environment.
• Lantheus Holdings, Inc. (NASDAQ: LNTH) dropped 8.5% to $56.03 after the company reported a proposed offering of $500 million convertible senior notes due 2027.
• Prime Medicine, Inc. (NASDAQ: PRME) fell 8.5% to $15.90.
• National Bank Holdings Corporation (NYSE: NBHC) fell 8.2% to $43.54.
• Rumble Inc. (NASDAQ: RUM) fell 8% to $8.06. Oppenheimer recently initiated coverage on Rumble with a Perform rating.
• Prime Medicine, Inc. (NASDAQ: PRME) fell 7.5% to $16.07.
• V.F. Corporation (NYSE: VFC) dropped 7.7% to $30.65 after the company said it expects total revenue growth in the second half of FY23 to be "modestly lower than previously outlined." The company also cut adjusted EPS guidance below estimates.
• Coupang, Inc. (NYSE: CPNG) fell 7.3% to $18.20.
• Nkarta, Inc. (NASDAQ: NKTX) dropped 7% to $7.99. The company announced updated data from its Phase 1 dose escalation study of NKX019 as monotherapy to treat patients with relapsed or refractory non-Hodgkin lymphoma.
• BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) fell 6.5% to $11.94. BioCryst recently announced approval of ORLADEYOO (berotralstat) by the Israeli Ministry of Health.

Check out this: Beachbody, Spectrum Pharmaceuticals And This Industrial Stock Under $1 Insiders Are Aggressively Buying